|
1
|
Wang C, Kar S, Lai X, Cai W, Arfuso F,
Sethi G, Lobie PE, Goh BC, Lim LHK, Hartman M, et al: Triple
negative breast cancer in Asia: An insider's view. Cancer Treat
Rev. 62:29–38. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumar P and Aggarwal R: An overview of
triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Ruijter TC, Veeck J, de Hoon JP, van
Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative
breast cancer. J Cancer Res Clin Oncol. 137:183–192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma P, López-Tarruella S, García-Saenz
JA, Khan QJ, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y,
Barnadas A, Picornell AC, et al: Pathological response and survival
in triple-negative breast cancer following neoadjuvant carboplatin
plus docetaxel. Clin Cancer Res. 24:5820–5829. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakashoji A, Matsui A, Nagayama A, Iwata
Y, Sasahara M and Murata Y: Clinical predictors of pathological
complete response to neoadjuvant chemotherapy in triple-negative
breast cancer. Oncol Lett. 14:4135–4141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nagao T, Kinoshita T, Hojo T, Tsuda H,
Tamura K and Fujiwara Y: The differences in the histological types
of breast cancer and the response to neoadjuvant chemotherapy: The
relationship between the outcome and the clinicopathological
characteristics. Breast. 21:289–295. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adams S, Gatti-Mays ME, Kalinsky K, Korde
LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E,
Perlmutter J, et al: Current landscape of immunotherapy in breast
cancer: A review. JAMA Oncol. Apr 11–2019.(Epub ahead of print).
doi: 10.1001/jamaoncol.2018.7147. View Article : Google Scholar
|
|
8
|
Bayraktar S, Batoo S, Okuno S and Glück S:
Immunotherapy in breast cancer. J Carcinog. 18:22019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Basile D, Pelizzari G, Vitale MG, Lisanti
C, Cinausero M, Iacono D and Puglisi F: Atezolizumab for the
treatment of breast cancer. Expert Opin Biol Ther. 18:595–603.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sinicrope FA, Rego RL, Ansell SM, Knutson
KL, Foster NR and Sargent DJ: Intraepithelial effector
(CD3+)/regulatory (FoxP3+) T-cell ratio
predicts a clinical outcome of human colon carcinoma.
Gastroenterology. 137:1270–1279. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ancuta E, Ancuţa C, Zugun-Eloae F,
Iordache C, Chirieac R and Carasevici E: Predictive value of
cellular immune response in cervical cancer. Rom J Morphol Embryol.
50:651–655. 2009.PubMed/NCBI
|
|
12
|
Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH,
Lee HE, Kim YJ, Kim JH and Park SY: Tumour-infiltrating
CD8+ lymphocytes as an independent predictive factor for
pathological complete response to primary systemic therapy in
breast cancer. Br J Cancer. 109:2705–2713. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu S, Lachapelle J, Leung S, Gao D,
Foulkes WD and Nielsen TO: CD8+ lymphocyte infiltration
is an independent favorable prognostic indicator in basal-like
breast cancer. Breast Cancer Res. 14:R482012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Loi S, Dushyanthen S, Beavis PA, Salgado
R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV,
et al: RAS/MAPK activation is associated with reduced
tumor-infiltrating lymphocytes in triple-negative breast cancer:
Therapeutic cooperation between MEK and PD-1/PD-L1 immune
checkpoint inhibitors. Clin Cancer Res. 22:1499–1509. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Denkert C, Loibl S, Noske A, Roller M,
Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R,
Hanusch C, et al: Tumor-associated lymphocytes as an independent
predictor of response to neoadjuvant chemotherapy in breast cancer.
J Clin Oncol. 28:105–113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamaguchi R, Tanaka M, Yano A, Tse GM,
Yamaguchi M, Koura K, Kanomata N, Kawaguchi A, Akiba J, Kanomata N,
et al: Tumor-infiltrating lymphocytes are important pathologic
predictors for neoadjuvant chemotherapy in patients with breast
cancer. Hum Pathol. 43:1688–1694. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ono M, Tsuda H, Shimizu C, Yamamoto S,
Shibata T, Yamamoto H, Hirata T, Yenemori K, Ando M, Tamura K, et
al: Tumor-infiltrating lymphocytes are correlated with response to
neoadjuvant chemotherapy in triple-negative breast cancer. Breast
Cancer Res Treat. 132:793–805. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brown JR, Wimberly H, Lannin DR, Nixon C,
Rimm DL and Bossuyt V: Multiplexed quantitative analysis of CD3,
CD8, and CD20 predicts response to neoadjuvant chemotherapy in
breast cancer. Clin Cancer Res. 20:5995–6005. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bloom HJ and Richardson WW: Histological
grading and prognosis in breast cancer. A study of 1409 cases of
which 359 have been followed for 15 years. Br J Cancer. 11:359–377.
1957. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
American Joint Committee on Cancer, . The
New Edition (7th) AJCC Staging System for Breast Cancer.
June;2010.http://cancerstaging.org/references-tools/deskreferences/Documents/AJCC%207th%20Ed%20Cancer%20Staging%20Manual.pdfOctober.
2019
|
|
21
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs Working Group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sahoo S and Lester SC: Pathology of breast
carcinomas after neoadjuvant chemotherapy: Overview with
recommendations on specimen processing and reporting. Arch Pathol
Lab Med. 133:633–642. 2009.PubMed/NCBI
|
|
23
|
Hammond ME, Hayes DF and Wolff AC:
Clinical Notice for American Society of Clinical Oncology-College
of American Pathologists guideline recommendations on ER/PgR and
HER2 testing in breast cancer. J Clin Oncol. 29:e4582011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rathore AS, Kurmar S, Konwar R, Makker A,
Negi MP and Goel MM: CD3+, CD4+,
CD8+ tumor infiltrating lymphocytes (TILs) are
predictors of favourable survival outcome in infiltrating ductal
carcinoma of breast. Indian J Med Res. 140:361–369. 2014.PubMed/NCBI
|
|
25
|
Santuario-Facio SK, Cardona-Huerta S,
Perez-Paramo YX, Trevino V, Hernandez-Cabrera F, Rojas-Martinez A,
Uscanga-Perales G, Martinez-Rodriguez JL, Martinez-Jacobo L,
Padilla-Rivas G, et al: A new gene expression signature for
triple-negative breast cancer using frozen fresh tissue before
neoadjuvant chemotherapy. Mol Med. 23:101–111. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miyan M, Schmidt-Mende J, Kiessling R,
Poschke I and de Boniface J: Differential tumor infiltration by
T-cells characterizes intrinsic molecular subtypes in breast
cancer. J Transl Med. 14:2272016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
R Core Team. R, . A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: 2014, http://ww=w.R-project.org/October. 2017
|
|
28
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. Nat
Genet. 25:25–29. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
The Gene Ontology Consortium, . The gene
ontology resource: 20 years and still going strong. Nucleic Acids
Res. 47:D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kanehisa M, Sato Y, Furumichi M, Morishima
K and Tanabe M: New approach for understanding genome variations in
KEGG. Nucleic Acids Res. 47:D590–D595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kanehisa M: Toward understanding the
origin and evolution of cellular organisms. Protein Sci.
28:1947–1951. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Szklarczyk D, Gable AL, Lyon D, Junge A,
Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork
P, et al: STRING v11: Protein-protein association networks with
increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic Acids Res. 47:D607–D613. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
von Mering C, Jensen LJ, Snel B, Hooper
SD, Krupp M, Foglierini M, Jouffre N, Huynen MA and Bork P: STRING:
Known and predicted protein-protein associations, integrated and
transferred across organisms. Nucleic Acids Res. 33:433–437. 2005.
View Article : Google Scholar
|
|
35
|
Cui X and Churchill GA: Statistical tests
for differential expression in cDNA microarray experiments. Genome
Biol. 4:2102003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee M, Tayyari F, Pinnaduwage D, Bayani J,
Bartlett JMS, Mulligan AM, Bull SB and Andrulis IL: Tumoral BRD4
expression in lymph node-negative breast cancer: Association with
T-bet+ tumor-infiltrating lymphocytes and disease-free
survival. BMC Cancer. 18:7502018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim ST, Jeong H, Woo OH, Seo JH, Kim A,
Lee ES, Shin SW, Kim YH, Kim JS and Park KH: Tumour-infiltrating
lymphocytes, tumour characteristics, and recurrence in patients
with early breast cancer. Am J Clin Oncol. 36:224–231. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mao Y, Qu Q, Zhang Y, Liu J, Chen X and
Shen K: The value of tumor infiltrating lymphocytes (TILs) for
predicting response to neoadjuvant chemotherapy in breast cancer: A
systematic review and meta-analysis. PLoS One. 9:e1151032014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rathore AS, Kumar S, Konwar R, Srivastava
AN, Makker A and Goel MM: Presence of CD3+ tumor
infiltrating lymphocytes is significantly associated with good
prognosis in infiltrating ductal carcinoma of breast. Indian J
Cancer. 50:239–244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang L, Conejo-Garcia JR, Katsaros D,
Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H,
Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence,
and survival in epithelial ovarian cancer. N Engl J Med.
348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim JY, Lee E, Park K, Park WY, Jung HH,
Ahn JS, Im YH and Park YH: Immune signature of metastatic breast
cancer: Identifying predictive markers of immunotherapy response.
Oncotarget. 8:47400–47411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Levy E, Marty R, Gárate Calderon V, Woo B,
Dow M, Armisen R, Carter H and Harismendy O: Immune DNA signature
of T cell infiltration in breast tumor exomes. Sci Rep.
6:300642016. View Article : Google Scholar : PubMed/NCBI
|
